Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085584 (
encephalopathy
)
18,178
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CYFIP2
, encoding the evolutionary highly conserved cytoplasmic FMRP interacting protein 2, has previously been proposed as a candidate gene for intellectual disability and autism because of its important role linking FMRP-dependent transcription regulation and actin polymerization via the WAVE regulatory complex (WRC). Recently, de novo variants affecting the amino acid p.Arg87 of
CYFIP2
were reported in four individuals with epileptic
encephalopathy
. We here report 12 independent patients harboring a variety of de novo variants in
CYFIP2
broadening the molecular and clinical spectrum of a novel
CYFIP2
-related neurodevelopmental disorder. Using trio whole-exome or -genome sequencing, we identified 12 independent patients carrying a total of eight distinct de novo variants in
CYFIP2
with a shared phenotype of intellectual disability, seizures, and muscular hypotonia. We detected seven different missense variants, of which two occurred recurrently (p.(Arg87Cys) and p.(Ile664Met)), and a splice donor variant in the last intron for which we showed exon skipping in the transcript. The latter is expected to escape nonsense-mediated mRNA decay resulting in a truncated protein. Despite the large spacing in the primary structure, the variants spatially cluster in the tertiary structure and are all predicted to weaken the interaction with WAVE1 or NCKAP1 of the actin polymerization regulating WRC-complex. Preliminary genotype-phenotype correlation indicates a profound phenotype in p.Arg87 substitutions and a more variable phenotype in other alterations. This study evidenced a variety of de novo variants in
CYFIP2
as a novel cause of mostly severe intellectual disability with seizures and muscular hypotonia.
...
PMID:Spatially clustering de novo variants in CYFIP2, encoding the cytoplasmic FMRP interacting protein 2, cause intellectual disability and seizures. 3066 14
The cytoplasmic FMR1-interacting protein family (CYFIP1 and
CYFIP2
) are evolutionarily conserved proteins originally identified as binding partners of the fragile X mental retardation protein (FMRP), a messenger RNA (mRNA)-binding protein whose loss causes the fragile X syndrome. Moreover, CYFIP is a key component of the heteropentameric WAVE regulatory complex (WRC), a critical regulator of neuronal actin dynamics. Therefore, CYFIP may play key roles in regulating both mRNA translation and actin polymerization, which are critically involved in proper neuronal development and function. Nevertheless, compared to CYFIP1, neuronal function and dysfunction of
CYFIP2
remain largely unknown, possibly due to the relatively less well established association between
CYFIP2
and brain disorders. Despite high amino acid sequence homology between CYFIP1 and
CYFIP2
, several in vitro and animal model studies have suggested that
CYFIP2
has some unique neuronal functions distinct from those of CYFIP1. Furthermore, recent whole-exome sequencing studies identified de novo hot spot variants of
CYFIP2
in patients with early infantile epileptic
encephalopathy
(EIEE), clearly implicating
CYFIP2
dysfunction in neurological disorders. In this review, we highlight these recent investigations into the neuronal function and dysfunction of
CYFIP2
, and also discuss several key questions remaining about this intriguing neuronal protein. [BMB Reports 2019; 52(5): 304-311].
...
PMID:Neuronal function and dysfunction of CYFIP2: from actin dynamics to early infantile epileptic encephalopathy. 3098 1